VanEck Pharmaceutical ETF (PPH)

NASDAQ: PPH · Real-Time Price · USD
92.43
-0.06 (-0.06%)
At close: Oct 24, 2025, 4:00 PM EDT
93.00
+0.57 (0.62%)
After-hours: Oct 24, 2025, 6:55 PM EDT
-0.06%
Assets$1.24B
Expense Ratio0.36%
PE Ratio19.53
Shares Out13.14M
Dividend (ttm)$1.94
Dividend Yield2.09%
Ex-Dividend DateOct 1, 2025
Payout FrequencyQuarterly
Payout Ratio40.89%
Volume665,720
Open92.24
Previous Close92.49
Day's Range92.24 - 92.88
52-Week Low77.67
52-Week High95.13
Beta0.54
Holdings26
Inception DateFeb 1, 2000

About PPH

Fund Home Page

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is issued by VanEck.

Asset Class Equity
Category Health
Region North America
Stock Exchange NASDAQ
Ticker Symbol PPH
ETF Provider VanEck
Index Tracked MVIS US Listed Pharmaceutical 25

Top 10 Holdings

73.80% of assets
NameSymbolWeight
Eli Lilly and CompanyLLY20.88%
Novartis AG ADRNVSN.MX9.73%
Merck & Co., Inc.MRK7.53%
Novo Nordisk A/SNVO7.23%
GSK plcGSK4.86%
McKesson CorporationMCK4.85%
Pfizer Inc.PFE4.82%
Johnson & JohnsonJNJ4.73%
AbbVie Inc.ABBV4.66%
SanofiSNY4.53%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Oct 1, 2025$0.3931Oct 6, 2025
Jul 1, 2025$0.6069Jul 7, 2025
Apr 1, 2025$0.5245Apr 4, 2025
Dec 27, 2024$0.411Dec 30, 2024
Oct 1, 2024$0.409Oct 4, 2024
Jul 1, 2024$0.3558Jul 5, 2024
Full Dividend History

Performance

PPH had a total return of 1.31% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.14%.

News

Final Trade: JCI, PPH, TOL, IBM

The final trades of the day with the Fast Money traders.

Other symbols: IBMJCITOL
18 days ago - CNBC Television

Drug Tariffs Are a Sideshow. Trump's Next Move Could Hit Pharma Harder.

What unnerves investors is a lack of clarity on drug pricing.

Other symbols: XPH
4 weeks ago - WSJ

Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability

Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.

Other symbols: XPHIHEPJP
4 weeks ago - WSJ

Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1

President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...

Other symbols: FTXHIHEXPH
4 weeks ago - Fast Company

Pharma stocks gain, as Trump's tariff move actually could be a win for the sector

Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.

Other symbols: PJPXPHIHE
4 weeks ago - Market Watch

PPH: Excellent Pharmaceutical ETF, But Bad Timing To Invest

VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings an...

5 weeks ago - Seeking Alpha

PPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And Center

I maintain a hold rating on PPH due to attractive valuation but weak technical momentum and underperformance versus the S&P 500. Eli Lilly and Johnson & Johnson, PPH's largest holdings, are facing uni...

3 months ago - Seeking Alpha

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

5 months ago - Seeking Alpha

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volati...

Other symbols: IHEXPH
6 months ago - Benzinga

PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger

VanEck Pharmaceutical ETF holds a mixed outlook due to high fees and tariff risks, warranting a hold rating despite strong top holdings. PPH's top holdings like Eli Lilly and Johnson & Johnson have di...

6 months ago - Seeking Alpha

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...

8 months ago - Seeking Alpha

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

10 months ago - Seeking Alpha

Final Trade: MSTR, PPH, TLT, MCD

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: MCDMSTRTLT
10 months ago - CNBC Television

Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH

The VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade from buy to hold. PPH's valuation has increased significantly, with a high p...

1 year ago - Seeking Alpha

PPH: A Strong Fund To Play Big Pharma

The Health Care sector bullish due to AI technology. VanEck Pharmaceutical ETF offers exposure to leading pharmaceutical companies. The defensive nature of the pharmaceutical sector makes it somewhat ...

1 year ago - Seeking Alpha

PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns

VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF has been in an uptrend since late last year and is currently trading at a ...

1 year ago - Seeking Alpha

PPH: Ignore The Election Scare, Buy Pharma And Healthcare

Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms...

1 year ago - Seeking Alpha

Healthcare In 2024: Navigating The Biopharma Bull Run

The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to...

Other symbols: FHLCIBBIYHVHTXBIXLV
1 year ago - Seeking Alpha

Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.

Other symbols: BMYJNJLLYPFE
2 years ago - Barrons

Biotech Stocks Are Rallying, but the Outlook Isn't Good

The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.

Other symbols: XBIXLV
2 years ago - Barrons

PPH: A 'Shot In The Arm' For Investors Looking To Capitalize On Recent Pharmaceutical Advances

VanEck Pharmaceutical ETF has had the strongest one-year performance of four major pharmaceutical ETF competitors due to its unique mix of Novo Nordisk, Eli Lilly, and Johnson & Johnson. Eli Lilly, PP...

2 years ago - Seeking Alpha

PPH: GLP-1 Companies And Large-Cap Value Pharma Make For A Compelling Portfolio

Eli Lilly is a mega-cap stock in the Health Care sector that has performed well in 2023, and it's the top holding in the VanEck Pharmaceutical ETF. I have a buy rating on the low-cost and style & geog...

2 years ago - Seeking Alpha

PPH: Unnecessary Volatility In A Relatively Stable Healthcare Sector (Technical Analysis)

Pharmaceutical ETFs like PPH may introduce another layer of risk that could be avoided if one took a broader approach to healthcare investing. Technical Analysis displays that beneath the most recent ...

2 years ago - Seeking Alpha

How The Pharmaceutical Industry Is Using AI

Industry-leading pharmaceutical firms are adopting artificial intelligence to drive value for the future of their enterprise. Several companies in the VanEck Pharmaceutical ETF are currently integrati...

Other symbols: AZNJNJMSFTNVS
2 years ago - Seeking Alpha

PPH Fell As Much As The Market Despite Resilience

The US market is highly speculative right now, as it's bid up to levels comparable to before stresses in the banking system had been revealed by SVB Financial. PPH, which follows a broad basket of the...

2 years ago - Seeking Alpha

The Fall Of SVB: What It Means For Healthcare Startups

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

Other symbols: BBCBBHFBTIBBIHEIHFIHI
2 years ago - Seeking Alpha

Betting On Biotech

Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow. Passive investors seeking a defensive position might just pu...

Other symbols: DVAMRNA
2 years ago - Seeking Alpha

PPH Might Be Too Safe For A Recovering Market

We think that the bear market is coming to an end, as it must. The way to go is to invest in higher beta, or at least in more beaten down issues.

3 years ago - Seeking Alpha

Can Health Care Stocks Outperform Again In 2023?

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

3 years ago - Seeking Alpha

PPH Investors Should Keep On Top Of Regulatory Developments

PPH investors own the whole world of bigger to big pharma, where wallet share is primarily in the U.S. Things are changing, however, with Medicare now able to negotiate prices with companies on the mo...

3 years ago - Seeking Alpha

What The Inflation Reduction Act Means For Drug Prices

The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs ...

Other symbols: BBCBBHIBBIHEIHFIHIIYH
3 years ago - Seeking Alpha

PPH: A Pharmaceutical ETF Delivering Close To 10% Total Return

Historically, PPH generated a steady total return with a low yield up to 2 percent. PPH's price multiples are considerably lower than its peers and index despite strong earnings and stable historical ...

3 years ago - Seeking Alpha

Pharma In Transition: Context And Opportunities

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

3 years ago - Seeking Alpha